Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 106
Filter
2.
Rev Neurol (Paris) ; 159(12): 1125-42, 2003 Dec.
Article in French | MEDLINE | ID: mdl-14978413

ABSTRACT

Involuntary movements, or dyskinesias, represent a debilitating complication of levodopa therapy for Parkinson's disease. Dyskinesia is, ultimately, experienced by the vast majority of the patients. Despite the importance of this problem, little was known about the cause of dyskinesia, a situation that has dramatically evolved in the last few years. The present review presents: 1) the current understanding of dyskinesia pathophysiology and 2) the therapeutic modalities, mainly non-dopaminergic, available or in development. We here show that the questions raised by the dyskinesia may have a clinically-driven pharmacological answer: the symptomatic treatment of dyskinesia, the prevention of the priming and the de-priming of the neural networks.


Subject(s)
Dopamine Agents/adverse effects , Dyskinesia, Drug-Induced/drug therapy , Dyskinesia, Drug-Induced/physiopathology , Levodopa/adverse effects , Animals , Basal Ganglia/anatomy & histology , Basal Ganglia/physiology , Disease Models, Animal , Dyskinesia, Drug-Induced/prevention & control , Humans , Receptors, Adrenergic/drug effects , Receptors, Adrenergic/physiology , Receptors, Dopamine/drug effects , Receptors, Dopamine/physiology , Receptors, Glutamate/drug effects , Receptors, Glutamate/physiology , Receptors, Opioid/drug effects , Receptors, Opioid/physiology , Receptors, Purinergic P1/drug effects , Receptors, Purinergic P1/physiology
3.
Biol Psychiatry ; 50(10): 813-6, 2001 Nov 15.
Article in English | MEDLINE | ID: mdl-11720701

ABSTRACT

INTRODUCTION: In the present study, we determined whether certain proteins known to mediate dopamine signaling in striatum show abnormal levels in Parkinson's disease. METHODS: Protein levels were assayed by western blotting in samples of caudate nucleus and putamen obtained at autopsy from patients with Parkinson's disease and from control subjects. Levels of several markers of dopaminergic function were also assayed. RESULTS: Levels of the transcription factor DeltaFosB and of the G protein modulatory protein RGS9 were both increased in caudate and putamen from patients with Parkinson's disease. Levels of several other proteins were not affected. Interestingly, levels of both DeltaFosB and RGS9 correlated inversely with putamen levels of dopamine, dopamine metabolites, and the dopamine transporter. CONCLUSIONS: These findings are consistent with observations in laboratory animals, which have demonstrated elevated levels of DeltaFosB in striatum after denervation of the midbrain dopamine system, and confirm that similar adaptations in DeltaFosB and RGS9 occur in humans with Parkinson's disease. Knowledge of these adaptations can help us understand the changes in striatal function associated with Parkinson's disease and assist in the development of novel treatments.


Subject(s)
Caudate Nucleus/pathology , Membrane Glycoproteins , Nerve Tissue Proteins , Parkinson Disease/pathology , Proto-Oncogene Proteins c-fos/analysis , Putamen/pathology , RGS Proteins/analysis , Blotting, Western , Dopamine/analysis , Dopamine Plasma Membrane Transport Proteins , Humans , Membrane Transport Proteins/analysis , Reference Values
5.
Synapse ; 40(3): 225-34, 2001 Jun 01.
Article in English | MEDLINE | ID: mdl-11304760

ABSTRACT

We investigated the effect of MPTP-induced lesion of the substantia nigra pars compacta (SNpc) dopaminergic neurons on GABA(B) receptors in the basal ganglia of mice and monkeys using receptor autoradiography and in situ hybridization. The extent of the lesion was measured with striatal catecholamine content, striatal binding of (125)I-RTI-121 to dopamine transporter (DAT), and DAT expression in the SNpc. GABA(B) receptors in mice brain were evaluated using (3)H-CGP54626 and its expression was measured with oligonucleotides probes targeting the mRNAs of GABA(B(1a+b)), GABA(B(1a)), GABA(B(1b)), GABA(B(2)) subunits. In monkeys, (125)I-CGP64213 and selective probes for GABA(B(1a+b)) and GABA(B(2)) mRNAs were used. In mice, dopamine content, (125)I-RTI-121 binding, and DAT expression were reduced by 44%, 40%, and 39% after a dose of 40 mg/kg of MPTP and 74%, 70%, and 34% after 120 mg/kg of MPTP, respectively. In monkeys, dopamine content and DAT expression were decreased by more than 90% and 80%, respectively. In the striatum and the subthalamic nucleus, GABA(B) receptors were unchanged following MPTP in both species. In the SNpc of mice, MPTP (120 mg/kg) induced a significant decrease of (3)H-CGP54626 binding (-10%) and of the expression of GABA(B(1a+b)) mRNA (-13%). The decrease of the expression of GABA(B(1a+b)) mRNA was correlated with dopamine content, (125)I-RTI-121 binding and DAT expression. In MPTP-treated monkeys, (125)I-CGP64213 binding (-40%), GABA(B(1a+b)) mRNA (-69%) and GABA(B(2)) mRNA (-66%) were also significantly decreased in the SNpc. Our results suggest that MPTP-induced denervation is associated with a decrease of GABA(B) receptors restricted to the SNpc. These observations may be relevant to the pathophysiology of motor disorders involving dysfunction of the basal ganglia such as Parkinson disease.


Subject(s)
Basal Ganglia/metabolism , Cocaine/analogs & derivatives , Dopamine/metabolism , Membrane Glycoproteins/metabolism , Membrane Transport Proteins/metabolism , Nerve Tissue Proteins/metabolism , Parkinsonian Disorders/metabolism , Receptors, GABA-B/metabolism , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , Animals , Basal Ganglia/physiopathology , Benzoates/metabolism , Cocaine/metabolism , Corpus Striatum/metabolism , Corpus Striatum/physiopathology , Disease Models, Animal , Dopamine Plasma Membrane Transport Proteins , Dose-Response Relationship, Drug , Female , Macaca fascicularis , Male , Mice , Mice, Inbred C57BL , Organophosphorus Compounds/metabolism , Parkinsonian Disorders/chemically induced , Parkinsonian Disorders/physiopathology , Protein Subunits/genetics , Protein Subunits/metabolism , RNA, Messenger/metabolism , Radioligand Assay , Receptors, GABA-B/genetics , Substantia Nigra/metabolism , Substantia Nigra/physiopathology , Subthalamic Nucleus/metabolism , Subthalamic Nucleus/physiopathology
6.
Eur J Pharmacol ; 412(3): 247-54, 2001 Feb 02.
Article in English | MEDLINE | ID: mdl-11166288

ABSTRACT

(S)-(-)-3-(3-(methylsulfonyl)phenyl)-1-propylpiperidine ((-)-OSU6162) is a phenylpiperidine derivative which exhibits low affinity to the dopamine D2 receptor in vitro. However, in vivo, positron emission tomography scanning studies show that the compound displaces the selective dopamine D2 receptor antagonist, raclopride. We have evaluated, in this study, the effect of (-)-OSU6162, on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a primate model of Parkinson's disease. Five 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated cynomolgus monkeys with a stable parkinsonian syndrome and reproducible dyskinesias to L-DOPA were used in this study. The monkeys were housed in observation cages equipped with an electronic motility monitoring system. They were injected subcutaneously (s.c.) with L-DOPA methyl ester (125 mg per animal) plus benserazide (50 mg per animal; L-DOPA/benserazide) alone or in combination with (-)-OSU6162 (1.0, 3.0, 6.0 or 10 mg/kg, s.c.). Subcutaneous injection of sterile saline was used as control. L-DOPA/benserazide increased locomotion and improved parkinsonism but also induced dyskinesias. Co-administration of (-)-OSU6162 with L-DOPA/benserazide produced a significant reduction in L-DOPA-induced dyskinesias. This improvement in L-DOPA-induced dyskinesias occurred mainly at the onset of the L-DOPA/benserazide effect as reflected by an increase in the duration of the "ON" state without dyskinesias up to 3.4 fold after (-)-OSU6162 co-administration as compared to L-DOPA/benserazide alone. The anti-dyskinetic effect of (-)-OSU6162 was maintained during 14 days and no tolerance to this effect was observed. Our data suggests that (-)-OSU6162 could be of significant clinical value to reduce L-DOPA-induced dyskinesias in fluctuating advanced Parkinson's disease patients.


Subject(s)
Dyskinesia, Drug-Induced/drug therapy , Levodopa/pharmacology , Parkinsonian Disorders/physiopathology , Piperidines/pharmacology , Receptors, Dopamine D2/metabolism , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pharmacology , Animals , Antiparkinson Agents/administration & dosage , Antiparkinson Agents/pharmacology , Benserazide/administration & dosage , Benserazide/pharmacology , Dopamine Agents/pharmacology , Dopamine Antagonists/pharmacology , Dopamine Antagonists/therapeutic use , Female , Humans , Levodopa/administration & dosage , Macaca fascicularis , Motor Activity/drug effects , Parkinsonian Disorders/drug therapy , Piperidines/therapeutic use
7.
Trends Neurosci ; 23(10 Suppl): S92-100, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11052226

ABSTRACT

The MPTP monkey is a well-characterized animal model of parkinsonism and provides an exceptional tool for the study of dyskinesias induced by dopamine-like agents. Several such agents have been tested during the past 15 years, and it has been found that the duration of action of these compounds is the most reliable variable with which to predict their dyskinesiogenic profile. It is proposed that L-dopa-induced dyskinesias represent a form of pathological learning caused by chronic pulsatile (nonphysiological) stimulation of dopamine receptors, which activates a cascade of molecular and biochemical events. These events include defective regulation of Fos proteins that belong to the deltaFosB family, increased expression of neuropeptides, and defective GABA- and glutamate-mediated neurotransmission in the output structures of the basal ganglia.


Subject(s)
Antiparkinson Agents/adverse effects , Basal Ganglia/drug effects , Dopamine Agonists/adverse effects , Dyskinesia, Drug-Induced/metabolism , Levodopa/adverse effects , Parkinsonian Disorders/metabolism , Receptors, Dopamine/drug effects , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , Animals , Antiparkinson Agents/administration & dosage , Basal Ganglia/metabolism , Disease Models, Animal , Dopamine Agonists/administration & dosage , Haplorhini , Levodopa/administration & dosage , Neural Inhibition , Neuropeptides/metabolism , Parkinsonian Disorders/chemically induced , Proto-Oncogene Proteins c-fos/metabolism , Receptors, Dopamine/metabolism , Receptors, GABA/metabolism , Receptors, Glutamate/metabolism , Signal Transduction
8.
Clin Neuropharmacol ; 23(4): 195-202, 2000.
Article in English | MEDLINE | ID: mdl-11020123

ABSTRACT

The pathophysiology of L-Dopa-induced dyskinesias (LID), a common problem after long-term use of L-dopa in the treatment of Parkinson's disease (PD), is not completely understood. Oscillations in L-Dopa concentrations in the brain are believed to be responsible, at least in part, for their pathogenesis. This study was aimed at verifying whether chronic administration of cabergoline, a long-acting dopamine D2-like receptor agonist, can reverse established LID. Four MPTP-treated cynomolgus monkeys with long-standing and stable parkinsonian syndrome and reproducible dyskinesias to L-Dopa, were used in this study. We compared the antiparkinsonian and dyskinetic responses of L-Dopa methyl ester (62.5 mg and 125 mg), given with benserazide (50 mg) (L-Dopa/benserazide), administered before and after a 6-week period during which the animals were treated only by daily administration of cabergoline (doses ranging from 0.125 to 0.185 mg/kg, subcutaneous). During cabergoline treatment, the monkeys initially showed marked dyskinesias, which were reduced significantly after 4 weeks of treatment. However, there was no tolerance to its antiparkinsonian effect. L-Dopa/benserazide given 4 days after cabergoline withdrawal produced a significant antiparkinsonian effect, but dyskinesias were dramatically reduced compared to what had been seen before chronic cabergoline treatment. The duration of the L-Dopa response was not increased after chronic administration of cabergoline. Our data suggest that sustained dopamine D2 receptor stimulation could be of value when trying to reduce or to reverse LID in patients with fluctuating advanced PD.


Subject(s)
Antiparkinson Agents/antagonists & inhibitors , Antiparkinson Agents/therapeutic use , Dyskinesia, Drug-Induced/drug therapy , Ergolines/therapeutic use , Levodopa/antagonists & inhibitors , Parkinson Disease, Secondary/complications , Animals , Antiparkinson Agents/toxicity , Behavior, Animal/drug effects , Benserazide/pharmacology , Cabergoline , Female , Levodopa/toxicity , Macaca fascicularis , Motor Activity/drug effects , Receptors, Dopamine D2/drug effects
9.
Article in English | MEDLINE | ID: mdl-10958154

ABSTRACT

1. Chronic treatment for one month with the long-acting dopamine D2-like agonist cabergoline (0.25 mg/kg s.c. every 48 hours), had despite partial tolerance, sustained antiparkinsonian activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Parkinsonian monkeys (Macaca fascicularis). 2. Cabergoline treatment decreased by half striatal D2 receptor binding density measured by [3H]spiperone autoradiography versus untreated MPTP monkeys. No change in D2 mRNA measured by in situ hybridization and D2 receptor immunostaining was observed. 3. No change in either D1 receptor binding density or D1 receptor mRNA levels was observed in cabergoline-treated MPTP-monkeys compared to untreated MPTP-monkeys, suggesting receptor subfamily specificity of cabergoline. 4. The present results suggest that the cabergoline-induced behavioral partial tolerance is accompanied by a decrease in D2 receptor binding but not due to alterations in the steady state of D2 mRNA levels.


Subject(s)
Antiparkinson Agents/pharmacology , Ergolines/pharmacology , Parkinson Disease/drug therapy , Receptors, Dopamine D1/drug effects , Receptors, Dopamine D2/drug effects , Animals , Antiparkinson Agents/administration & dosage , Binding Sites , Cabergoline , Disease Models, Animal , Ergolines/administration & dosage , Female , In Situ Hybridization , Macaca fascicularis , Parkinson Disease/physiopathology , Receptors, Dopamine D1/physiology , Receptors, Dopamine D2/physiology
10.
Eur J Pharmacol ; 399(2-3): 183-6, 2000 Jul 07.
Article in English | MEDLINE | ID: mdl-10884518

ABSTRACT

Clozapine reduces L-3,4-dihydroxyphenylalanine (L-Dopa)-induced dyskinesias in parkinsonian patients. To test if the antidyskinetic effect of clozapine is related to antagonism at the dopamine D(4) receptor, we investigated the effect of 8-methyl-6-(4-methyl-1-piperazinyl)-11H-pyrido[2,3-b][1, 4]benzodiazepine (JL-18), a structural analog of clozapine which is more selective for this receptor. Four 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-treated cynomolgus monkeys with a stable parkinsonian syndrome and reproducible dyskinesias to L-Dopa were used in this study. They were injected subcutaneously (s.c.) with L-Dopa methyl ester (125 mg per animal) plus benserazide (50 mg per animal; L-Dopa/benserazide) alone or in combination with JL-18 (at the doses of 0.1, 0.3, or 0.9 mg/kg, s.c.). Subcutaneous injection of sterile saline was used as control. L-Dopa/benserazide increased locomotion and improved parkinsonism but also induced dyskinesias. Co-administration of JL-18, at low doses (0.1, 0.3 mg/kg) with L-Dopa/benserazide, produced a dose-dependent reduction in L-Dopa-induced dyskinesias without a parallel return to parkinsonism. The present results suggest that novel selective dopamine D(4) receptor antagonists may represent a useful tool to reduce L-Dopa-induced dyskinesias.


Subject(s)
Clozapine/analogs & derivatives , Clozapine/pharmacology , Dyskinesia, Drug-Induced/prevention & control , Parkinsonian Disorders/drug therapy , Analysis of Variance , Animals , Antiparkinson Agents/pharmacology , Behavior, Animal/drug effects , Benserazide/pharmacology , Dose-Response Relationship, Drug , Female , Levodopa/pharmacology , Macaca fascicularis , Motor Activity/drug effects , Parkinsonian Disorders/physiopathology
11.
Ann Neurol ; 47(4 Suppl 1): S70-8, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10762134

ABSTRACT

A series of experiments were performed in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of parkinsonism for the purpose of understanding the mechanism of dopaminergic dyskinesias. Dyskinesias can be induced in this model by de novo treatment with levodopa, or selective D1 or D2 agonists, provided the drugs are short acting and administered in the pulsatile mode. Biochemical analysis of the brains revealed several alterations in dopamine receptor-binding and messenger RNA message following denervation and dopaminergic treatment, but none that clearly correlated with the presence of dyskinesias. On the other hand, gamma-aminobutyric acid (GABA)A binding was increased in the internal segment of the globus pallidus of dyskinetic MPTP monkeys. This was observed consistently and could be associated with an exaggerated response to GABAergic inhibitory inputs in this strategic structure. Increased preproenkephalin message was also found to correlate with dyskinesias and may be linked to changes in GABA receptors. Treatments that caused dyskinesias induced, in the striatum, chronic Fos proteins of the deltaFosB family which, when coupled with Jun-D, form AP-1 complexes that can affect several genes, including enkephalin and N-methyl-D-aspartate receptor. We suggest that levodopa-induced dyskinesias represent a form of pathological learning, which results from deficient gating of glutamatergic inputs to the striatum by dopamine.


Subject(s)
Brain Chemistry/genetics , Dopamine Agents/adverse effects , Dyskinesia, Drug-Induced/genetics , Levodopa/adverse effects , Parkinson Disease/drug therapy , Animals , Brain Chemistry/drug effects , Gene Expression/drug effects , Humans
12.
Exp Neurol ; 163(1): 191-9, 2000 May.
Article in English | MEDLINE | ID: mdl-10785458

ABSTRACT

Much evidence indicates that abnormal GABA neurotransmission may be implicated in the pathophysiology of Parkinson's disease (PD) and dopaminomimetic-induced dyskinesias (DID). In this study, autoradiography using (125)I-CGP 64213 was performed to investigate GABA(B) receptor density in the brain of control monkeys as well as monkeys with MPTP-induced nigrostriatal depletion. Three MPTP monkeys received pulsatile administrations of the D1 dopamine (DA) receptor agonist (SKF 82958) whereas a long-acting D2 DA receptor agonist (cabergoline) was given to another three animals. SKF 82958 treatment relieved parkinsonian symptoms but two of three animals developed DID. Cabergoline induced a comparable motor benefit effect without persistent DID. (125)I-CGP 64213 binding to GABA(B) receptors was heterogeneous throughout the brain with the highest levels in the medial habenula of the thalamus. MPTP induced a decrease (-40%) of (125)I-CGP 64213 binding to GABA(B) receptors in the substantia nigra pars compacta (SNpc) and an increase (+29%) in the internal segment of the globus pallidus (GPi). This increase in the GPi was not affected by SKF 82958 but partly reversed by cabergoline. No change was seen in the striatum, the thalamus, the external segment of the globus pallidus, and the substantia nigra pars reticulata following MPTP and dopaminomimetic treatments. The changes of GABA(B) receptors observed in the SNpc and in the GPi suggest that alteration of GABA(B) receptors may play a role in the pathophysiology of PD and DID.


Subject(s)
Benzoates/metabolism , Brain/metabolism , GABA Antagonists/metabolism , Organophosphorus Compounds/metabolism , Parkinson Disease, Secondary/metabolism , Receptors, GABA-B/metabolism , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , Animals , Antiparkinson Agents/pharmacology , Autoradiography , Basal Ganglia/drug effects , Basal Ganglia/metabolism , Basal Ganglia/pathology , Benzazepines/pharmacology , Binding Sites , Brain/drug effects , Brain/pathology , Cabergoline , Corpus Striatum/drug effects , Dopamine Agonists/pharmacology , Drug Administration Schedule , Dyskinesia, Drug-Induced/metabolism , Ergolines/pharmacology , Female , GABA-B Receptor Antagonists , Injections, Subcutaneous , Iodine Radioisotopes , Macaca fascicularis , Parkinson Disease, Secondary/chemically induced , Parkinson Disease, Secondary/drug therapy , Substantia Nigra/drug effects , Substantia Nigra/pathology , Thalamus/drug effects , Thalamus/metabolism , Thalamus/pathology
13.
Naunyn Schmiedebergs Arch Pharmacol ; 361(2): 181-6, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10685874

ABSTRACT

Treatment of Parkinson's disease with L-dopa is plagued in a majority of patients by dyskinesias. Noradrenaline/dopamine interactions are proposed on behavioral, biochemical, physiological and anatomical grounds. The aim of the study was to test the potential antidyskinetic effect of the alpha2-adrenoceptor antagonist, idazoxan, in a primate model of Parkinson's disease. Six female cynomolgus monkeys previously rendered parkinsonian by the toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and presenting an unchanged syndrome for several months were used. All responded readily to L-dopa but had developed dyskinesias which were manifested with each dose. In the first part of the study, seven doses of idazoxan (ranging from 0.25 mg/kg to 10 mg/kg, p.o.) were administered together with the vehicle or in combination with a fixed dose of L-dopa/benserazide (100/25 mg, p.o.). In the second part of the study, a fixed dose of idazoxan (7.5 mg/kg) was administered daily for 10 days and L-dopa was added to idazoxan on days 1, 4, 7 and 10. Vehicle (empty capsule) was used as control. Idazoxan, by itself (ranging from 5 mg/kg to 10 mg/kg), increased locomotor activity and improved the disability score with virtually no dyskinesias in three animals. In combination with L-dopa, idazoxan did not impair the antiparkinsonian response but significantly reduced dyskinesias in all six animals up to 65% at doses of 7.5 mg/kg and 10 mg/kg and delayed their onset, so that the "ON" state without dyskinesias was prolonged. The antidyskinetic effect of idazoxan was maintained when repeatedly administered for 10 days. On day 10, the locomotor response to L-dopa was significantly potentiated by chronic administration of idazoxan. Our results indicate that idazoxan has some antiparkinsonian effect of its own and may constitute a useful adjunct to L-dopa as it can reduce dyskinesias without impairing the relief of symptoms, this effect being maintained over time in this model.


Subject(s)
Adrenergic alpha-2 Receptor Antagonists , Adrenergic alpha-Antagonists/therapeutic use , Antiparkinson Agents/therapeutic use , Dyskinesia, Drug-Induced/prevention & control , Idazoxan/therapeutic use , Levodopa/toxicity , Parkinson Disease/drug therapy , Animals , Dose-Response Relationship, Drug , Female , MPTP Poisoning/drug therapy , Macaca fascicularis , Motor Activity/drug effects , Norepinephrine/physiology , gamma-Aminobutyric Acid/metabolism
14.
Clin Neuropharmacol ; 22(5): 281-7, 1999.
Article in English | MEDLINE | ID: mdl-10516879

ABSTRACT

We assessed the antiparkinsonian response in MPTP-treated monkeys after acute or repeated treatment with oral L-Dopa, subcutaneous administration of L-Dopa methyl ester (LDME) or apomorphine, alone and in combination with D1 antagonists SCH 23390 (SCH) or NNC 01-0112 (NNC). When given alone, the L-Dopa effect occurred within the first hour after treatment. Coadministration of SCH or NNC with L-Dopa significantly delayed the onset of action. The response duration remained unchanged, as did the extent of the antiparkinsonian effect, after SCH, whereas the former became shorter at the higher doses of NNC tested. Bypass of the gastrointestinal tract using parenteral injections of LDME and apomorphine allowed the rapid turning "on" of the animals. Both D1 antagonists administered with LDME delayed the onset and shortened the duration of the therapeutic effect as the dose increased. Pretreatment with SCH failed to block the antiparkinsonian effect induced by apomorphine, but reduced the response duration markedly in a dose-related fashion. Repeated treatment of one monkey with SCH combined with the same dopaminergic drugs produced results similar to those obtained after acute treatment in four animals. The results obtained with parenteral administration of LDME and apomorphine most probably involve pharmacodynamic actions resulting in increased threshold of response. The delay observed with L-Dopa suggests pharmacokinetic interference possibly mediated via dopamine receptors located at the level of the gut.


Subject(s)
Behavior, Animal/drug effects , Benzazepines/pharmacology , Dopamine Agents/therapeutic use , Dopamine Antagonists/pharmacology , MPTP Poisoning/drug therapy , Animals , Antiparkinson Agents/therapeutic use , Apomorphine/therapeutic use , Digestive System/drug effects , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Administration Routes , Drug Interactions , Drug Therapy, Combination , Female , Levodopa/analogs & derivatives , Levodopa/therapeutic use , MPTP Poisoning/physiopathology , Macaca fascicularis , Time Factors
16.
Eur J Pharmacol ; 378(3): 259-63, 1999 Aug 13.
Article in English | MEDLINE | ID: mdl-10493101

ABSTRACT

The density of dopamine D1 receptor antagonist sites was measured by autoradiography and dopamine D1 receptor mRNA levels were measured by in situ hybridization in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed monkeys chronically treated with the dopamine D1 receptor agonist 6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benza zep ine hydrobromide (SKF-82958) administered in intermittent or continuous mode for a month. Normal and MPTP-exposed but otherwise untreated animals were used for comparison. Intermittent treatment with SKF-82958 relieved parkinsonian features and induced dyskinesias whereas given continuously this drug induced behavioral tolerance without dyskinesias. On the one hand, MPTP treatment tended to increase dopamine D1 receptor density in the putamen whereas treatment of MPTP monkeys with SKF-82958, intermittent or continuous, produced a significant increase compared to control animals. On the other hand, dopamine D1 receptor mRNA levels in the putamen appeared to decrease after MPTP lesion and agonist treatment as compared to dopamine D1 receptor density. In contrast, an apparent decrease in dopamine D1 receptor density and mRNA levels was observed in the nucleus accumbens of untreated MPTP monkeys whereas treatment of MPTP monkeys with SKF-82958, intermittent or continuous, produced a significant decrease compared to control animals. Thus, neither dyskinesias nor tolerance can be exclusively related to an increase or decrease in striatal dopamine D1 receptors, respectively.


Subject(s)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pharmacology , Benzazepines/pharmacology , Corpus Striatum/drug effects , Dopamine Agonists/pharmacology , RNA, Messenger/drug effects , Receptors, Dopamine D1/drug effects , Animals , Caudate Nucleus/drug effects , Caudate Nucleus/metabolism , Corpus Striatum/metabolism , Dopamine/metabolism , Dopamine Agents/pharmacology , Macaca fascicularis , Nucleus Accumbens/drug effects , Nucleus Accumbens/metabolism , Putamen/drug effects , Putamen/metabolism , RNA, Messenger/metabolism , Receptors, Dopamine D1/genetics , Receptors, Dopamine D1/metabolism
17.
Neurochem Int ; 35(1): 81-91, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10403433

ABSTRACT

The effect of various chronic dopaminergic treatments in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys on the brain gamma-aminobutyric acid type A (GABA(A)) /benzodiazepine receptor complex and GABA content was investigated in order to assess the GABAergic involvement in dopaminomimetic-induced dyskinesia. Three MPTP monkeys received for one month pulsatile administrations of the D1 dopamine (DA) receptor agonist SKF 82958 whereas three others received the same dose of SKF 82958 by continuous infusion. A long acting D2 DA receptor agonist, cabergoline, was given to another three animals. Untreated MPTP as well as naive control animals were also included. Pulsatile SKF 82958 relieved parkinsonian symptoms but was also associated with dyskinesia in two of the three animals whereas animals treated continuously with SKF 82958 remained as untreated MPTP monkeys. Chronic cabergoline administration improved motor response with no persistent dyskinesia. MPTP treatment induced a decrease of 3H-flunitrazepam binding in the medial anterior part of caudate-putamen and an increase in the internal segment of globus pallidus (GPi) which was in general unchanged by pulsatile or continuous SKF 82958 administration. Throughout the striatum, binding of 3H-flunitrazepam remained reduced in MPTP monkeys treated with cabergoline but was not significantly lower than untreated MPTP monkeys. Moreover, cabergoline treatment reversed the MPTP-induced increase in 3H-flunitrazepam binding in the GPi. GABA concentrations remained unchanged in the striatum, external segment of globus pallidus and GPi following MPTP denervation. Pulsatile but not continuous SKF 82958 administration decreased putamen GABA content whereas cabergoline treatment decreased caudate GABA. No alteration in GABA levels were observed in the GPe and GPi following the experimental treatments. These results suggest that: (1) D2-like receptor stimulation with cabergoline modulates GABA(A) receptor density in striatal subregions anatomically related to associative cortical afferent and (2) the absence of dyskinesia in dopaminomimetic-treated monkeys might be associated with the reversal of the MPTP-induced upregulation of the GABA(A)/benzodiazepine receptor complex in the Gpi.


Subject(s)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pharmacology , Basal Ganglia/metabolism , Benzazepines/pharmacology , Dopamine Agonists/pharmacology , Ergolines/pharmacology , Receptors, Dopamine D1/physiology , Receptors, Dopamine D2/physiology , Receptors, GABA-A/metabolism , gamma-Aminobutyric Acid/metabolism , Animals , Autoradiography , Basal Ganglia/drug effects , Cabergoline , Denervation , Female , Flunitrazepam/pharmacokinetics , Macaca fascicularis , Ovariectomy , Receptors, Dopamine D1/agonists , Receptors, Dopamine D2/agonists , Receptors, GABA-A/drug effects , Tritium
18.
Neurology ; 52(8): 1673-7, 1999 May 12.
Article in English | MEDLINE | ID: mdl-10331698

ABSTRACT

BACKGROUND: Chronic treatment with L-3,4-dihydroxyphenylalanine (L-dopa) is often associated with motor side effects in PD patients. The search for new therapeutic approaches has led to study the role of other neuromodulators including adenosine. Among the four adenosine receptors characterized so far, the A2A subtype is distinctively present on striatopallidal output neurons containing enkephalin and mainly bearing dopamine (DA) D2 receptors (indirect pathway). Studies in DA-denervated rats suggest that blockade of adenosine A2A receptors might be used in PD. OBJECTIVE: To evaluate the antiparkinsonian effect of a new selective adenosine A2A receptor antagonist, KW-6002, in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys. METHODS: In the present study, we used six MPTP-exposed cynomolgus monkeys already primed and exhibiting L-dopa-induced dyskinesias to evaluate both the antiparkinsonian and dyskinetic effect upon challenge with two oral doses (60 and 90 mg/kg) of KW-6002 administered alone or in combination with L-dopa/benserazide (50/12.5 mg). RESULTS: KW-6002 administered alone produced a dose-dependent antiparkinsonian response that reached the level of efficacy of L-dopa/benserazide but was less likely to reproduce dyskinesias in these animals. When co-administered, KW-6002 potentiated the effects of L-dopa/benserazide on motor activity (up to 30%) without affecting the dyskinetic response. CONCLUSION: Adenosine A2A receptor antagonists have antiparkinsonian effects of their own with a reduced propensity to elicit dyskinesias. They might therefore be useful agents in the treatment of PD.


Subject(s)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/adverse effects , Levodopa/pharmacology , Parkinson Disease, Secondary/chemically induced , Purinergic P1 Receptor Antagonists , Purines/pharmacology , Animals , Brain/drug effects , Female , Levodopa/therapeutic use , Locomotion/drug effects , Macaca fascicularis , Parkinson Disease, Secondary/drug therapy , Purines/therapeutic use , Receptor, Adenosine A2A
19.
Synapse ; 32(3): 153-64, 1999 Jun 01.
Article in English | MEDLINE | ID: mdl-10340626

ABSTRACT

The effect of denervation with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) of the dopamine (DA) nigrostriatal pathway on neurotensin (NT) receptor and DA transporter (DAT) in basal ganglia of monkeys (Macaca fascicularis) was investigated. The MPTP lesion induced a marked depletion of DA (90% or more vs. control) in the caudate nucleus and putamen. The densities of NT agonist binding sites labeled with [125I]NT and the NT antagonist binding sites labeled with [3H]SR142948A decreased by half in the caudate-putamen of MPTP-monkeys. In addition, the densities of [125I]NT and [3H]SR142948A binding sites markedly decreased (-77 and -63%, respectively) in the substantia nigra of MPTP-monkeys. Levocabastine did not compete with high affinity for [125I]NT binding in the monkey cingulate cortex, suggesting that only one class of NT receptors was labelled in the monkey brain. An extensive decrease of [3H]GBR12935 DAT binding sites (-92% vs. Control) was observed in the striatum of MPTP-monkeys and an important loss of DAT mRNA(-86% vs. Control) was observed in substantia nigra. Treatments for 1 month with either the D1 agonist SKF-82958 (3 mg/kg/day) or the D2 agonist cabergoline (0.25 mg/kg/day) had no effect on the lesion-induced decrease in NT and DAT binding sites or DAT mRNA levels. The decrease of striatal NT binding sites was less than expected from the decrease of DA content in this nucleus, suggesting only partial localization of NT receptors on nigrostriatal DAergic projections. These data also suggest that under severe DA denervation, treatment with D1 or D2 DA agonists does not modulate NT receptors and DAT density.


Subject(s)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pharmacology , Carrier Proteins/metabolism , Dopamine Agents/pharmacology , Membrane Glycoproteins , Membrane Transport Proteins , Neostriatum/drug effects , Nerve Tissue Proteins , Receptors, Neurotensin/metabolism , Substantia Nigra/drug effects , Adamantane/analogs & derivatives , Adamantane/metabolism , Animals , Autoradiography , Binding Sites/drug effects , Carrier Proteins/genetics , Caudate Nucleus/drug effects , Caudate Nucleus/metabolism , Denervation , Dopamine/metabolism , Dopamine Agents/metabolism , Dopamine Plasma Membrane Transport Proteins , Dose-Response Relationship, Drug , Down-Regulation/drug effects , Imidazoles/metabolism , In Situ Hybridization , Macaca fascicularis , Neostriatum/metabolism , Neurotensin/metabolism , Piperidines/metabolism , Putamen/drug effects , Putamen/metabolism , RNA, Messenger/analysis , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Dopamine/metabolism , Receptors, Neurotensin/agonists , Receptors, Neurotensin/antagonists & inhibitors , Substantia Nigra/metabolism
20.
Neurology ; 52(4): 771-6, 1999 Mar 10.
Article in English | MEDLINE | ID: mdl-10078726

ABSTRACT

OBJECTIVE: To determine whether dopamine (DA) D1 or DA D2 receptors are associated predominantly with the antiparkinsonian versus the dyskinetic effect of levodopa. METHODS: The authors used four L-dopa-primed, dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys to test whether acute and selective blockade of the DA D1 receptor subtype, using SCH 23390 and NNC 01-112, could reduce L-dopa-induced dyskinesias without altering the relief of symptoms. Blockade of DA receptors using sulpiride (D2) and clozapine (D1-D2-like) was studied for comparison. RESULTS: With the notable exception of the lowest dose of clozapine tested, coadministration of DA D1 or D2 antidopaminergic agents with L-dopa reduced the L-dopa-induced dyskinesias but also caused a return of parkinsonian disability. Prolonged latencies from intake of a single oral dose of L-dopa to turning "on," decreased duration of the "on" state, and a complete failure to induce benefit was also observed. CONCLUSION: Low-dose clozapine could be an effective adjunct to reduce L-dopa-induced dyskinesias without altering the relief of parkinsonian symptoms. Interactions with many neurotransmitter systems may explain the better pharmacologic profile of clozapine, including DA D4 (rather than D1), serotonin, acetylcholine, and noradrenaline. Neither dyskinesias nor antiparkinsonian effects can be ascribed solely to the D2 or D1 receptor. Thus, some cooperation between the two receptors appears necessary for these behavioral effects.


Subject(s)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/adverse effects , Levodopa/therapeutic use , Movement Disorders/drug therapy , Parkinson Disease, Secondary/chemically induced , Receptors, Dopamine D1/antagonists & inhibitors , Animals , Behavior, Animal/drug effects , Female , Locomotion/drug effects , Macaca fascicularis
SELECTION OF CITATIONS
SEARCH DETAIL
...